MDCXW — Medicus Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1997296 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -14,460,256 | -15,181,335 | 14,536,679 | 5,019,755 | 25,026,436 |
| Jun 2026 | 0 | — | -11,478,789 | -11,617,705 | 27,116,185 | 15,174,128 | 28,841,149 |
| Mar 2026 | 0 | — | -8,597,077 | -9,042,143 | 7,426,911 | 6,365,624 | 5,999,017 |
| Dec 2025 | 0 | — | -7,790,600 | -8,184,411 | 10,061,377 | 8,705,218 | 10,024,066 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,320,075
Investing CF
$0
Financing CF
$49,379,679
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-85,007,966
Inventory
—
Receivables
$14,000
ST Investments
—
EBIT TTM
$-43,363,328
Pretax Income TTM
$-44,892,607
Interest Exp TTM
$580,350
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,359,302 | -35,444,215 | 10,061,377 | 10,024,066 | -67,554 | -22,776,769 |
| Dec 2024 | 0 | -11,180,902 | -11,155,516 | 5,646,878 | 2,512,174 | 3,134,704 | -10,247,231 |
| Dec 2023 | 0 | -2,658,365 | -5,314,765 | 1,893,057 | 781,609 | 1,111,448 | -4,158,264 |
| Dec 2022 | 0 | -978,416 | -1,692,382 | 282,652 | 12,480,684 | -12,198,032 | -1,057,103 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-56,662,869
OpCashFlow TTM
—
Assets (Latest)
$27,116,185
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Medicus Pharma raises $4.25M in CEO-led financings
2026-11-16 14:45 · Yahoo
Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt Exchange
2026-11-16 12:30 · Yahoo
Medicus Pharma shares rationale as CD228V becomes lead development priority
2026-11-10 16:48 · Yahoo
Medicus Pharma Ltd (MDCX) Q3 2026 Earnings Call Highlights: Pfizer ADC License, SkinJet SPAC ...
2026-11-10 05:03 · Yahoo
Medicus Pharma (MDCX) Q3 2026 Earnings Call Transcript
2026-11-09 21:49 · Yahoo
Medicus Pharma sharpens focus on Pfizer-licensed cancer drug CD228V, trims costs in Q3
2026-11-09 13:33 · Yahoo
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
2026-11-09 12:30 · Yahoo
Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline
2026-11-09 12:19 · Yahoo
Medicus Pharma Ltd. Common Stock Q3 2026 Earnings Call Summary
2026-11-07 13:30 · Yahoo
Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-06 21:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.